Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.German biopharmaceutical firm CureVac has concluded exploratory discussions with the European Commission (EC) on an advanced purchase agreement (APA) for the company’s mRNA-based Covid-19 vaccine candidate.
The proposed contract will provide all European Union (EU) member states with up to 225 million doses, with an option for an additional of 180 million doses, made if the vaccine candidate is safe and effective.